Table 2.
Tumor characteristics and neoadjuvant interventions.
| Characteristic | Study cohort (n=187) |
|---|---|
| Tumor location, n (%) | |
| Head | 71 (38) |
| Head/body/neck | 76 (41) |
| Body/neck/tail | 1 (0.5) |
| Body/neck | 38 (20) |
| Head/tail | 1 (0.5) |
| Tumor size (cm), n (%) | |
| < 2 | 4 (2) |
| 2.1 - 3 | 84 (45) |
| >3 | 99 (53) |
| Vascular involvement, n (%) | |
| Single Arterial alone (SMA or Celiac) | 19 (10) |
| Venous Alone | 19 (10) |
| Arterial + Venous | 77 (41) |
| Both Arterial (SMA and Celiac) | 72 (39) |
| Induction chemotherapy, n (%) | |
| FOLFIRINOX alone | 42 (22) |
| FOLFIRINOX + gemcitabine/abraxane | 62 (33) |
| Gemcitabine/abraxane | 19 (10) |
| Other Combinations (5FU Alone, PARP Inhibitor, Gemcitabine and Cisplatin, FOLFOX, FOLFIRI) | 64 (34) |
| Prior radiation therapy, n (%) | |
| 3-D conformal | 37 (20) |
| SBRT | 15 (8) |
| Prior local therapy/surgery, n (%) | |
| IRE | 4 (2) |
| Pancreatic resection | 3 (2) |
| Percent drop in CA19-9, n (%) | |
| < 0 | 32 (17) |
| 0 - 58 | 40 (21) |
| 59 - 86 | 34 (18) |
| 87 - 96 | 47 (25) |
| > 96% | 34 (18) |
SBRT, stereotactic body radiation therapy; IRE, irreversible electroporation; CA19-9, cancer antigen 19-9; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin.